Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial - Schopohl, J; Gu, F; Rubens, R; Van Gaal, L; Bertherat, J; Ligueros-Saylan, M; Trovato, A; Hughes, G; Salgado, L R; Boscaro, M; Pivonello, R (Pituitary, 2015)